TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23860366
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) therapy at 67 µg/kg/day for 1 year
Study: 21170205
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Withania somnifera and Terminalia arjuna (500mg/day each)
Study: 21170205
Drug: Placebo (capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsules filled with flour)
Study: 17684475
Drug: NRTIs (nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs (nucleoside reverse transcriptase inhibitors)
Study: 16648247
Drug: Low-dose melatonin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose melatonin administration in the morning
Study: 16648247
Drug: Low-dose melatonin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose melatonin administration in the afternoon/evening
Study: 16648247
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light exposure (treatment of choice)
Study: 11128877
Drug: Toluene exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toluene exposure (measured by urinary excretion of unmodified toluene)
Study: 11128877
Drug: Cumulative toluene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative toluene exposure (estimated as product of urinary excretion and previous exposure duration)
Study: 8799521
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg day‐1 for 1 week)
Study: 1395875
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus preoperative chemotherapy
Study: 31612147
Drug: Propolis spray
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis spray (3%) applied to cover the entire wound surface during dressing changes from week 0 until cicatrization or a maximum of 8 weeks.
Study: 31612147
Drug: Propolis spray
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis spray (3%)
Study: 29443664
Drug: Nusinersen (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nusinersen (12 mg, intrathecal administration on days 1, 29, 85, and 274)
Study: 27908454
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg intramuscular injection (days 0, 14, 28, then every 28 days thereafter)
Study: 27908454
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg orally daily
Study: 22422103
Drug: Immuno-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-chemotherapy
Study: 15772570
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d combined with MPA 2.5 mg/d (n = 20)
Study: 15772570
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d combined with MPA 5 mg/d (n = 20)
Study: 15772570
Drug: Unopposed CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed CEE 0.625 mg/d (n = 20)
Study: 10406359
Drug: Vigabatrin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 2 g daily
Study: 10406359
Drug: Carbamazepine 600
Normalized name: carbamazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 600 mg daily
Study: 7776521
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of fentanyl 10‐13 micrograms.kg‐1 during lower abdominal surgery under light general anesthesia (halothane 0.3‐0.5% plus nitrous oxide and oxygen)
Study: 7776521
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural anesthesia (intermittent injections of 1.0% lidocaine) during lower abdominal surgery under light general anesthesia
Study: 7776521
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia (intermittent injections of 1.0% lidocaine) during upper abdominal surgery under light general anesthesia
Study: 2222129
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of short half-life benzodiazepines
Study: 2222129
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of long half-life benzodiazepines
Study: 8740611
Drug: Active drugs
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drugs
Study: 26605240
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus atypical antipsychotic
Study: 18752540
Drug: IntraSite Gel
Normalized name: Intrasite Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IntraSite Gel (hydrogel)
Study: 11069572
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg or budesonide 200 microg, prescribed twice daily
Study: 11069572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - beta2-agonist only
Study: 9235813
Drug: Piroxicam-beta-cyclodextrin 20
Normalized name: piroxicam-beta-cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam-beta-cyclodextrin 20 mg daily for 14 days
Study: 9235813
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg daily for 14 days
Study: 1441691
Drug: slow-release gallopamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release gallopamil, 100 mg b.i.d.
Study: 1441691
Drug: slow-release nifedipine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release nifedipine, 20 mg b.i.d.
Study: 29570019
Drug: CP (37%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP (37% carbamide peroxide gel)
Study: 29570019
Drug: HP (35%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP (35% H2O2 gel)
Study: 29570019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bleaching agent)
Study: 11858475
Drug: Low-molecular-weight heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously
Study: 11858475
Drug: Unfractionated sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously
Study: 10074877
Drug: Clozapine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (maximum dose of 300 mg/day)
Study: 10074877
Drug: Chlorpromazine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (maximum dose of 600 mg/day)
Study: 2024753
Drug: Lignocaine 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.5% with 1/200,000 adrenaline (group L)
Study: 7215756
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (7,500 i.u. subcutaneous twice daily)
Study: 7215756
Drug: Semi-synthetic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-synthetic heparin analogue (5,000 U subcutaneous twice daily)
Study: 30591535
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (LDCT) lung cancer screening
Study: 19775999
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy after breast-conserving surgery (BCS)
Study: 19775999
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy after complete mastectomy
Study: 19775999
Drug: Breast conservative
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservative surgery without radiation therapy
Study: 7793647
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (150 mg)
Study: 7793647
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine (150 mg)
Study: 1903598
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone infusion (45 ng.kg‐1.min‐1)
Study: 7017100
Drug: Droperidol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.05 mg/kg, intravenously administered)
Study: 23373664
Drug: Partial directly
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial directly observed antiretroviral therapy (DOT‐ART)
Study: 23373664
Drug: Self‐administered ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered ART (Self‐ART)
Study: 20031735
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine (2 x 120 microg in 20 mL NaCl)
Study: 20031735
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 x 20 mL NaCl)
Study: 17352768
Drug: IL-2 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 (7.5 MIU twice a day, for 5 days every 8 weeks)
Study: 12365878
Drug: ethyl-eicosapentaenoate 1
Normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ethyl-eicosapentaenoate 1 g/d
Study: 12365878
Drug: ethyl-eicosapentaenoate 2
Normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ethyl-eicosapentaenoate 2 g/d
Study: 12365878
Drug: ethyl-eicosapentaenoate 4
Normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ethyl-eicosapentaenoate 4 g/d
Study: 9521435
Drug: Beta-carotene and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene and vitamin A supplementation (30 mg of beta-carotene and 25,000 IU of retinyl palmitate)
Study: 7855556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tobramycin and cefuroxime (T/C)
Study: 2535678
Drug: usual anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual anti-hypertensive therapy
Study: 31917100
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day of ferrous sulfate
Study: 21711174
Drug: Soy (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (2 mg/kg body weight aglycone equivalent isoflavones)
Study: 21711174
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of seaweed (5 g/day) and soy
Study: 18064563
Drug: Fluoxetine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (daily oral for 6 months)
Study: 26009003
Drug: High-intensity games
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity games intervention (twice-weekly, 40 min sessions for 6 weeks)
Study: 25591636
Drug: XR‐NTX (380
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR‐NTX (380 mg)
Study: 18680075
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (0.1 mg bolus, then 35 microg/kg/min for 6 hours, maximum dose 9 mg)
Study: 15647969
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU intranasal salmon calcitonin (Miacalcic nasal 200) daily, 1 month on-1 month off, 0.25 mug 1alpha(OH)D3, and 500 mg elemental calcium continuously
Study: 15647969
Drug: 0.25 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mug 1alpha(OH)D3 and 500 mg elemental calcium
Study: 12034414
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor antagonists
Study: 12034414
Drug: Losartan (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (reference drug)
Study: 8017601
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 300 micrograms
Study: 1093426
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 10 mg
Study: 9752388
Drug: Therapeutic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic mixture containing 10 mg of methylphenidate, 2.5 mg of methandrostenolone, and a mixture of B vitamins
Study: 15475141
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.05 mg/kg/day
Study: 11501649
Drug: Nickel sulfate
Normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulfate patch test
Study: 11501649
Drug: Potassium dichromate
Normalized name: Potassium dichromate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium dichromate patch test
Study: 29947487
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (40 ml of 0.25% solution)
Study: 20450425
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with 400 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine during operation and 200 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine 21 h postoperatively
Study: 20450425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no injections during operation and saline injection 21 h postoperatively
Study: 18481390
Drug: Oregovomab immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oregovomab immunotherapy
Study: 16527015
Drug: Tisseel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisseel (2 cc)
Study: 12660408
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CrH2O) supplementation (0.5 g x kg(‐1) FFM, one fourth dosage 4 times daily for 5 days)
Study: 9014620
Drug: Neostigmine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (doses > 20 micrograms kg-1)
Study: 3926591
Drug: Cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 600 mg b.i.d.
Study: 31032782
Drug: Memory rehabilitation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memory rehabilitation (10 weekly sessions of a manualised memory rehabilitation programme)
Study: 29418016
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment with Sex Steroid Replacement Therapy (SSRT)
Study: 26817525
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 50 mg
Study: 22329446
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (physical therapy, topical dimethyl sulfoxide, analgesics, transcutaneous stimulation, sympathetic blockade)
Study: 15744348
Drug: Intravenous 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 6-mercaptopurine (1 g/m(2))
Study: 15744348
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous 6-mercaptopurine (Control Group, Arm A)
Study: 12173072
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg once a day for two days prior to HA and during initial three days at HA
Study: 91437
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cis-platinum (1-hour infusion with mannitol diuresis)
Study: 91437
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cis-platinum (8-hour infusion without diuresis)
Study: 91437
Drug: Three-drug program
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug program (vinblastine, actinomycin D, and cis-platinum)
Study: 91437
Drug: Cyclic crossover
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic crossover regimen (three regimens each containing three drugs)
Study: 30854443
Drug: DCE-MRI before
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCE-MRI before radiation therapy (pre-RT)
Study: 30854443
Drug: DCE-MRI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCE-MRI after 2 weeks of radiation therapy (2wkRT)
Study: 27657674
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg) plus best supportive care
Study: 25461393
Drug: alendronate 70mg
Normalized name: ALENDRONATE 70MG TAB
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alendronate 70mg weekly
Study: 10772372
Drug: Personalized follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized follow-up (weekly telephone contact for 12 weeks)
Study: 3537249
Drug: Methionyl human
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl human growth hormone (0.125 mg/kg three times per week)
Study: 3537249
Drug: Oxandrolone (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.125 mg/kg/day)
Study: 3537249
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (hGH plus oxandrolone)
Study: 28222552
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) approach
Study: 21601839
Drug: Judgments based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Judgments based on the agent's innocent intent regarding accidental harms.
Study: 21601839
Drug: Judgments based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Judgments based on the agent's guilty intent regarding failed attempts to harm.
Study: 17003082
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg every other day
Study: 8196788
Drug: Preoperative instruction
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative instruction and physical therapy
Study: 8196788
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative instruction and physical therapy
Study: 3359548
Drug: Low-residue diet
Normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-residue diet with an additional intake of 1200 Kcal and 32 g protein daily (Group B)
Study: 3359548
Drug: Uninterrupted colonic
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted colonic preparation with dietary restrictions for 4-8 days (450 calories; 25 g proteins daily) (Group A)
Study: 20925067
Drug: Pramipexole 0.5
Normalized name: pramipexole 0.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.5 mg bid
Study: 20925067
Drug: Pramipexole 0.75
Normalized name: pramipexole 0.75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.75 mg bid
Study: 20925067
Drug: Pramipexole 0.5
Normalized name: pramipexole 0.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.5 mg tid
Study: 16740918
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment (TT)
Study: 15541014
Drug: Atipamezole (three-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole (three-step infusion aiming for serum concentrations of 10, 30, and 90 ng ml(‐1))
Study: 15541014
Drug: Atipamezole (three-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atipamezole (three-step infusion)
Study: 8491246
Drug: Nitecapone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitecapone 100 mg t.d.s. for 7 days
Study: 3555605
Drug: 0.25% idoxuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% idoxuridine ointment applied twice daily for 2 weeks
Study: 3555605
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied twice daily for 2 weeks
Study: 30032937
Drug: Individually-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually-based treatment (IBT)
Study: 30032937
Drug: Behavioral couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couples therapy plus individually-based treatment (BCT + IBT)
Study: 27311248
Drug: Dulaglutide (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (subcutaneous 0.75 or 1.5 mg once weekly)
Study: 27311248
Drug: Metformin, sitagliptin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, sitagliptin, exenatide, insulin glargine
Study: 25333428
Drug: Dental care
Normalized name: Arm And Hammer Dental Care Mint Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental care provided by a dental surgeon, 4‐5 times a week, including routine oral hygiene, teeth brushing, tongue scraping, removal of calculus, atraumatic restorative treatment of caries, and tooth extraction
Study: 25333428
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral hygiene only, including the use of chlorhexidine as a mouth rinse, performed by ICU nurse staff
Study: 25333428
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral hygiene only